Rare Disease · United States · In-Market

US Gaucher Disease Competitive Intelligence

Five FDA-approved Gaucher type 1 therapies (three IV enzyme replacement vs two oral substrate reduction) and eliglustat's oral first-line pivot.

5 FDA-approved therapies3 IV ERT vs 2 oral SRTIn-MarketUpdated Q3 2026
Market United States Stage
The Landscape

Enzyme replacement therapy built the Gaucher type 1 market over three decades — now oral eliglustat competes as the only first-line oral therapy, and the mechanism contest is ERT versus substrate reduction.

Gaucher disease type 1 (non-neuronopathic) accounts for more than 90% of Gaucher cases and is the only form with disease-modifying therapy addressing its visceral, hematologic, and skeletal manifestations. The US market splits by mechanism. Enzyme replacement therapy (ERT) replaces deficient acid β-glucosidase and is delivered by intravenous infusion: imiglucerase (Cerezyme, Sanofi/Genzyme, approved May 1994), velaglucerase alfa (VPRIV, Takeda, March 2010), and taliglucerase alfa (Elelyso, Pfizer, May 2012). Substrate reduction therapy (SRT) is oral and inhibits glucosylceramide synthase to lower substrate load: eliglustat (Cerdelga, Sanofi, 2014) and miglustat (Zavesca, Actelion/Janssen, 2003).

The commercial contest is route and line of therapy. Eliglustat is the only first-line oral therapy for adults with Gaucher type 1, but its label restricts use to CYP2D6 extensive, intermediate, or poor metabolizers identified by an FDA-cleared test — a genotype gate absent from ERT. In the ENGAGE trial, previously untreated patients on eliglustat had a 30% placebo-adjusted reduction in spleen volume, a 1.22 g/dL hemoglobin increase, and a 41% platelet rise at 9 months (JAMA 2015). Miglustat, approved a decade earlier, is positioned narrowly — for mild-to-moderate type 1 patients for whom ERT is not a therapeutic option — and now faces generic competition. The result is a mature, high-cost market where the strategic question is IV incumbency versus oral convenience.

5
FDA-approved Gaucher type 1 therapies across ERT and SRT mechanisms · Drugs@FDA
30%
eliglustat placebo-adjusted reduction in spleen volume at 9 months, ENGAGE · JAMA 2015 (PMID 25688781)
>90%
share of Gaucher patients with type 1 (non-neuronopathic) disease · Nalysnyk 2016 (PMID 27762169)
DRUG LANDSCAPE

FDA-approved Gaucher disease type 1 therapies — United States, 2026

Drug (Brand / INN)MechanismCompanyRouteUS ApprovalKey Trial / Positioning
Cerezyme (imiglucerase)Enzyme replacement (ERT)Sanofi / GenzymeIV infusionMay 1994First ERT; standard of care; dosing 2.5–60 U/kg
VPRIV (velaglucerase alfa)Enzyme replacement (ERT)TakedaIV infusionMar 2010Gene-activated human enzyme; every-other-week infusion
Elelyso (taliglucerase alfa)Enzyme replacement (ERT)Pfizer / ProtalixIV infusionMay 2012Plant-cell-expressed enzyme; adults with type 1
Cerdelga (eliglustat)Substrate reduction (SRT), oralSanofi / GenzymeOral capsuleAug 2014ENGAGE: spleen −30% vs placebo; only first-line oral; CYP2D6-gated
Zavesca (miglustat)Substrate reduction (SRT), oralActelion / JanssenOral capsuleJul 2003Mild–moderate type 1 when ERT not an option; now generic

Sources: FDA Drugs@FDA (BLA020367, BLA022575, BLA022458, NDA205494, NDA021348); ENGAGE, JAMA 2015 (PMID 25688781); Cerdelga and Zavesca FDA prescribing information.

Commercial Questions

What this brief answers

Every section answers a named commercial question your team is asking, scoped to your asset.

01
How do the three IV enzyme replacement therapies and the two oral substrate reduction therapies differentiate on mechanism, route, efficacy and line of therapy?

Delivers

  • ERT vs SRT mechanism and the IV-versus-oral split
  • efficacy across ENGAGE and ENCORE
  • dosing and infusion burden by agent
  • where line of therapy separates first-line oral eliglustat from the rest
02
What does eliglustat's oral first-line position (gated by CYP2D6 metabolizer status) mean for enzyme replacement incumbency and prescriber switching?

Delivers

  • The CYP2D6 metabolizer eligibility gate and its effect on addressable population
  • switching considerations in a chronic infused market
  • positioning against three decades of ERT incumbency
03
How do price, generic miglustat entry and benefit routing shape competitive access across the Gaucher type 1 market?

Delivers

  • Annual cost by agent
  • Part B infusion routing vs Part D oral routing
  • generic miglustat's low-end anchor
  • preferred-ERT designation as a payer lever

Custom brief delivered in 72 hours.

Commission This Brief
Contents

What's inside

Rare Disease · 24–32 pp · In-Market · Analyst report + Excel model + PowerPoint readout

1 Market Map: ERT vs SRT, IV vs Oral, Line of Therapy 4 pp
  • Five FDA-approved Gaucher type 1 therapies split into three IV enzyme-replacement agents and two oral substrate-reduction agents
  • Type 1 accounts for more than 90% of Gaucher cases and is the only form with disease-modifying therapy, setting the addressable market
2 Drug Profiles: Imiglucerase, Velaglucerase, Taliglucerase, Eliglustat, Miglustat 8 pp
  • Imiglucerase (1994), velaglucerase alfa (2010) and taliglucerase alfa (2012): three IV enzyme-replacement agents from Sanofi/Genzyme, Takeda, and Pfizer/Protalix
  • Eliglustat (2014) and miglustat (2003): the two oral substrate-reduction agents and their distinct label positioning
3 The Eliglustat Oral First-Line Contest & the CYP2D6 Gate 4 pp
  • In ENGAGE, previously untreated patients on eliglustat saw a 30% placebo-adjusted spleen-volume reduction, 1.22 g/dL hemoglobin increase, and 41% platelet rise at 9 months
  • Eliglustat's label restricts use to CYP2D6 extensive, intermediate or poor metabolizers identified by an FDA-cleared test, a genotype gate absent from any ERT agent
4 Enzyme Replacement Incumbency & Switching Dynamics 4 pp
  • Cerezyme has anchored the ERT market since 1994, three decades of incumbency that any oral or newer IV agent must displace
  • Miglustat is positioned narrowly for mild-to-moderate type 1 patients for whom ERT is not a therapeutic option, and now faces generic competition
5 Pricing, Generics & Payer Access 5 pp
  • IV enzyme-replacement agents route through the medical benefit (Part B) while oral eliglustat and miglustat route through the pharmacy benefit (Part D)
  • Generic miglustat sets the market's low-cost anchor, while payers use preferred-ERT designation among the three infused agents as a negotiating lever
6 Pipeline & Next-Generation Gaucher Approaches 3 pp
  • The bar next-generation Gaucher therapies must clear: ENGAGE's 30% spleen-volume reduction without ERT's IV infusion burden or eliglustat's CYP2D6 genotype gate
  • Where three decades of ERT incumbency and a genotype-restricted oral option leave room for a next mechanism to broaden first-line eligibility
Appendix and source ledger included · 45-minute analyst readout included with delivery
Formats

Included with every brief

PDF
PDF Brief
US Gaucher CI Brief — Complete Edition
25–30 page analyst brief: ERT vs SRT competitive map, five drug profiles, the eliglustat oral first-line contest, pricing and pipeline.
XLS
Excel Model
Drug Comparison & Payer Grid
Drug-by-drug comparison (mechanism, route, company, approval, trial) and payer/pricing dynamics in editable Excel.
PPT
PowerPoint
Executive Readout — PowerPoint
12–15 slide readout deck for commercial team presentations, formatted to AXLRx design standards.
Methodology

How AXLRx builds this brief

Prepared by MoatRx analysts.

Every AXLRx brief is built from primary regulatory sources (FDA Drugs@FDA, ClinicalTrials.gov), peer-reviewed literature, and live payer and HTA documentation — not secondary summaries, market-research reports, or unverified estimates. Findings are independently verified before inclusion; if a figure cannot be sourced to a live record, it does not ship.

US Gaucher Disease Competitive Intelligence sources: FDA Drugs@FDA approval records (BLA020367 imiglucerase, BLA022575 velaglucerase alfa, BLA022458 taliglucerase alfa, NDA205494 eliglustat, NDA021348 miglustat), the ENGAGE randomized trial (JAMA 2015, PMID 25688781), and the Cerdelga and Zavesca FDA prescribing information.

  • Approval status, routes and applicants verified against FDA Drugs@FDA (BLA020367, BLA022575, BLA022458, NDA205494, NDA021348)
  • Eliglustat efficacy verified against the ENGAGE randomized trial, JAMA 2015 (PMID 25688781)
  • Eliglustat first-line status and CYP2D6 metabolizer restriction verified against the Cerdelga FDA prescribing information
  • Miglustat second-line positioning verified against the Zavesca FDA prescribing information
FAQ

Frequently asked questions

Landscape
What therapies are approved for Gaucher disease type 1 in the US?
Five FDA-approved therapies span two mechanisms. Three intravenous enzyme replacement therapies (ERT) replace the deficient enzyme: imiglucerase (Cerezyme), velaglucerase alfa (VPRIV) and taliglucerase alfa (Elelyso). Two oral substrate reduction therapies (SRT) reduce glucosylceramide production: eliglustat (Cerdelga) and miglustat (Zavesca). Eliglustat is the only first-line oral option, restricted to CYP2D6 extensive, intermediate or poor metabolizers.
Competition
Why is eliglustat's launch significant for the Gaucher market?
Eliglustat is the only first-line oral therapy for Gaucher type 1, offering an alternative to lifelong intravenous infusion. In the ENGAGE trial it reduced spleen volume 30% versus placebo with hemoglobin and platelet gains. Its CYP2D6 metabolizer gate narrows the eligible population and functions as a payer utilization-management lever, while three IV enzyme replacement therapies retain a three-decade incumbency.
Deliverables
What formats are included with every brief?
Every commissioned brief includes three deliverables: a 20–30 page PDF analyst brief with verified sources and exhibit tables, an editable Excel model, and a 10–15 slide PowerPoint readout deck. An optional 60-minute analyst readout call is included with all deliveries.
Get Started

Commission this brief

AXLRx delivers US Gaucher disease type 1 competitive intelligence built for pharma and biotech commercial, access, and medical affairs teams. Custom brief in 72 hours.

1
Submit your request

Use the intake form to specify your indication, geography, and commercial question.

2
Scoping call

AXLRx analyst confirms scope, comparators, and delivery format.

3
Delivery

Research-verified brief in 72 hours with optional analyst readout.